Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Enrollment complete in phase I trial of MOR-208

May 22, 2012

FDA accepts amendment to Northwest's DCVax-L trial in brain cancer

May 18, 2012

Amgen provides updated blinatumomab results

May 17, 2012

FDA approves TG Therapeutics' IND for phase I/II ublituximab study

May 16, 2012

Recombinant vectors targeting NY-ESO-1 assessed in phase II trials

May 16, 2012

L-DOS-47 begins phase I/II study for NSCLC

May 15, 2012

Biovest plans to seek European marketing approval for cancer vaccine

May 15, 2012

Mologen study meets primary endpoint

May 14, 2012

Transgene gives update on development of HPV vaccine candidate

May 10, 2012

ImmunoCellular Therapeutics advances phase II ICT-107 trial

May 10, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2026.
AAIC 2026: Age of amyloid is being joined by time of tau
BioWorld
The Alzheimer’s Association International Conference (AAIC) is the world’s biggest dementia conference. And at the AAIC 2026 meeting, there is big buzz around...
Celia trial: data strong, analysts skeptical
BioWorld
Tuesday brought what was arguably the most anticipated presentation of the 2026 Alzheimer’s Association International Conference when Catherine Mummery, head of...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 14, 2026
Voyager’s gene therapy reduces tau levels in AD models
BioWorld Science
At the Alzheimer’s Association International Conference, researchers from Voyager Therapeutics Inc. presented preclinical efficacy data for VY-1706, a blood-brain...